Boston Scientific Prices €4.25B Six-Tranche Euro Notes to Fund Penumbra Deal
BSX is trading near its 52-week low of $39.57 (8.7% above the low).
Summary
Boston Scientific priced €4.25 billion of guaranteed senior notes in six euro tranches to fund the cash consideration for its ~$14.5 billion Penumbra acquisition, with settlement December 1, 2026.
Key Events · Financing and Capital Events · BSX
-
€4.25B Six-Tranche Euro Notes Priced
The six tranches comprise €500M 2-yr FRN at EURIBOR+63bp, €500M 2028 at 3.875%, €750M 2030 at 4.125%, €750M 2034 at 4.500%, €1.0B 2038 at 4.750% and €750M 2046 at 5.125%, all guaranteed by Boston Scientific.
-
Proceeds Fund Penumbra Cash Consideration
Net proceeds, together with a concurrent USD notes offering, short-term borrowings and cash on hand, will finance the cash consideration for the ~$14.5 billion Penumbra Acquisition and related fees.
-
Deal-Failure Redemption at 101%
The four fixed-rate tranches must be redeemed at 101% of principal plus accrued interest if the Penumbra Acquisition is not completed by the Special Mandatory Redemption End Date or Boston Scientific abandons it.
-
Settlement December 1, 2026
Trade date is November 19, 2026, with T+8 settlement on December 1, 2026; the notes list on Euronext Dublin's Global Exchange Market and clear through Clearstream and Euroclear.
Analysis · BSX · Industrial Applications And Services
The Dutch finance arm of Boston Scientific has locked in €4.25 billion of senior notes across six tranches, ranging from a 2-year floater at EURIBOR plus 63bp to a 20-year fixed at 5.125%. Because the proceeds fund the cash portion of the ~$14.5 billion Penumbra acquisition, this is debt-funded M&A rather than dilution: existing shareholders are not diluted, but leverage rises, and the four fixed-rate tranches carry a 101% special mandatory redemption if the deal does not close by the stated end date. Investment-grade ratings (A3/A-/A-) kept coupons moderate, with the 12-year tranche the largest single piece at €1.0 billion.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSX was trading at $43.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $62.3B. The 52-week trading range was $39.57 to $101.91. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.